Accuray Reports Fiscal 2027 First Quarter Financial Results

Accuray’s fiscal Q1 2027 revenue fell 8% year over year to $86.5 million; product revenue declined 26% to $27.3 million, while service revenue rose 4% to $59.2 million. Gross orders halved to $19.8 million, and backlog was down approximately 31% year over year to $272.0 million. Reported net income of $10.1 million included a $59.6 million non-cash debt-extinguishment gain and a $35.4 million goodwill impairment; excluding both, the company reported a $14.0 million net loss, while adjusted EBITDA improved to $2.5 million from negative $4.1 million. Accuray cited financing steps intended to reduce leverage and improve liquidity, but provided no formal fiscal 2027 revenue or adjusted EBITDA guidance.

Analysis

The key signal is commercial deterioration, not the reported GAAP profit: the debt-extinguishment gain and goodwill impairment obscure an underlying loss, while cost actions improved adjusted EBITDA. Those savings buy time but cannot offset a shrinking product engine if orders do not recover. Net orders below zero alongside weak gross orders and a sharply lower backlog raise a further concern: cancellations or other order reductions may be undermining the pipeline, not just delaying installations. Verify the composition of net orders and backlog conversion on today’s call.

Service is the stabilizer: pricing and installed-base growth support recurring revenue and margin, but this cushion is unlikely to replace new-system demand indefinitely. The RaySearch and Samsung NeuroLogica collaborations may help differentiation over a multi-year horizon; near-term value depends on product readiness, customer adoption, and orders, none of which is established by partnership announcements or clinical evidence alone. A broader radiation-therapy adoption benefit could accrue to competitors such as Elekta and Siemens Healthineers’ Varian as well, so clinical validation is not uniquely monetizable by Accuray.

Near term, the financing is a two-sided catalyst: completion could reduce debt pressure, but the proposed debt-for-preferred-equity exchange may shift risk toward common shareholders through dilution or preferred claims. Do not treat the accounting gain as cash or assume the exchange is closed. The contrarian case is that service resilience, lower costs, and improved clinical evidence create a floor; however, that floor is conditional on order stabilization. Over the next 1–3 months, order trends and financing completion matter more than cost-exclusion metrics. Over 6–18 months, execution and product competitiveness determine whether the installed-base economics can support recovery.

Key Decisions for Investors

• Avoid buying the GAAP earnings headline. For an existing ARAY position, keep exposure small pending the call; require evidence of order stabilization and financing completion before adding. Key checks: net versus gross orders, cancellations, backlog conversion, and terms/dilution of the preferred exchange.
• Tactical bearish watch: consider a small, defined-risk ARAY put spread or short only if the stock rallies on adjusted EBITDA or the non-cash debt gain without a credible order recovery. Reassess if subsequent quarterly gross orders recover and backlog stops contracting; a financing close or positive order surprise creates squeeze risk.
• Treat service growth and margin improvement as a partial offset, not a standalone bullish thesis. Falsification of the cautious view would be sustained product-order improvement, positive net orders, and stronger product revenue without renewed cash or covenant pressure; confirm liquidity runway and financing terms before sizing any trade.